Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119202) titled 'Comprehensive clinical evaluation of CDK4/6 inhibitors in the treatment of hormone receptor-positive /HER-2 negative advanced breast cancer' on Feb. 24.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Weihai Municipal Hospital
Condition:
Hormone receptor-positive HER-2 negative advanced breast cancer
Intervention:
Palbociclib:None
Abemaciclib:None
Dalpiciclib:None
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2024-12-12
Target Sample Size: Palbociclib:157;Abemaciclib:157;Dalpiciclib:157;Ribociclib:157;
Countries of Recruitment:
China
To know more...